Theragnostics, a rapidly evolving field in nuclear medicine, integrates diagnostic imaging and targeted therapy using radiopharmaceuticals. This personalized approach enhances precision in the detection and treatment of various diseases, particularly cancer. By utilizing radiolabeled compounds that bind to specific molecular targets, clinicians can visualize disease progression and simultaneously deliver therapeutic doses to affected tissues. The growing availability of novel radiotracers, improved imaging techniques, and advances in radionuclide therapy have transformed patient management, reducing side effects and improving treatment efficacy. Despite these advancements, challenges remain in optimizing radiopharmaceutical development, patient selection, and preclinical/clinical implementation.
This Research Topic aims to explore the latest developments, challenges, and future directions in theragnostic within nuclear medicine. Key objectives include improving the efficacy and safety of theragnostic agents, enhancing imaging biomarkers, and expanding clinical applications beyond oncology. Additionally, contributions addressing novel radiopharmaceuticals, personalized treatment approaches, and the integration of artificial intelligence in imaging analysis are encouraged. By fostering collaboration among nuclear medicine specialists, oncologists, radiochemists, and physicists, this collection seeks to advance the clinical translation of theragnostic and promote evidence-based strategies for precision medicine.
We welcome original research, reviews, clinical studies, and technological advancements focusing on:
• Development and optimization of theragnostic radiopharmaceuticals
• Preclinical and clinical applications in oncology and non-oncological diseases
• Advances in imaging techniques for patient stratification
• Dosimetry and radiobiology considerations in theragnostic therapies
• Artificial intelligence and machine learning applications in nuclear medicine
• Regulatory and ethical aspects of theragnostic implementation
Authors from diverse scientific and clinical backgrounds are encouraged to contribute, fostering multidisciplinary collaboration to shape the future of theragnostic in nuclear medicine.
Article types and fees
This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:
Brief Research Report
Case Report
Clinical Trial
Editorial
FAIR² Data
FAIR² DATA Direct Submission
General Commentary
Hypothesis and Theory
Methods
Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.
Article types
This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
